Soleno Therapeutics, Inc.SLNONASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank90
3Y CAGR+85.0%
5Y CAGR+0.0%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
+85.0%/yr
vs -51.3%/yr prior
5Y CAGR
+0.0%/yr
Recent acceleration
Acceleration
+136.2pp
Accelerating
Percentile
P90
Near historical high
vs 5Y Ago
1x
Modest growth
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 66.68% |
| Q3 2025 | 652.53% |
| Q2 2025 | 89.24% |
| Q1 2025 | 21.81% |
| Q4 2024 | 26.93% |
| Q3 2024 | -250.58% |
| Q2 2024 | -2.13% |
| Q1 2024 | -89.43% |
| Q4 2023 | -4.01% |
| Q3 2023 | -28.15% |
| Q2 2023 | -1.42% |
| Q1 2023 | -52.31% |
| Q4 2022 | 10.53% |
| Q3 2022 | 8.82% |
| Q2 2022 | -17.49% |
| Q1 2022 | -102.40% |
| Q4 2021 | 65.26% |
| Q3 2021 | 25.92% |
| Q2 2021 | -22.72% |
| Q1 2021 | -213.96% |
| Q4 2020 | 66.62% |
| Q3 2020 | -15.72% |
| Q2 2020 | -26.05% |
| Q1 2020 | 59.95% |
| Q4 2019 | -1745.11% |
| Q3 2019 | 108.88% |
| Q2 2019 | -42.36% |
| Q1 2019 | -2773.00% |
| Q4 2018 | 109.61% |
| Q3 2018 | 64.17% |
| Q2 2018 | -103.38% |
| Q1 2018 | 25.28% |
| Q4 2017 | -32.74% |
| Q3 2017 | 4.54% |
| Q2 2017 | -37.37% |
| Q1 2017 | -10.48% |
| Q4 2016 | 4.97% |
| Q3 2016 | 21.72% |
| Q2 2016 | -10.16% |
| Q1 2016 | -12.11% |